The company will start a phase 2/3 trial of PF-08634404 in March.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The group reports responses with its CD123-targeting ADC, but cash is running short.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
